ResMed Inc. (RMD)

ResMed Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Year	2023	2022	2021	2020	2019
Net Income	897.56	779.44	474.51	621.67	404.59
Depreciation & Amortization	197.56	193.84	191.52	181.37	150.8
Share-Based Compensation	71.14	65.26	63.93	57.56	52.07
Other Operating Activities	-472.96	-687.39	6.77	-58.35	-148.41
Operating Cash Flow	693.3	351.15	736.72	802.26	459.05
Operating Cash Flow Growth	97.44%	-52.34%	-8.17%	74.76%	-9.10%
Capital Expenditures	-119.67	-134.84	-102.71	-95.33	-68.71
Acquisitions	-1,012.75	-42.78	-39.07	-27.91	-951.38
Change in Investments	-13.1	-31.1	-2.57	-46.01	-46.98
Other Investing Activities	-14.33	-21.2	-14.11	-10.61	-8.63
Investing Cash Flow	-1,159.85	-229.92	-158.46	-179.86	-1,075.71
Dividends Paid	-258.28	-245.34	-226.71	-225.09	-211.71
Share Issuance / Repurchase	49.14	47.38	37.79	48.18	13.88
Debt Issued / Paid	665	122	-522	-94.01	807.49
Other Financing Activities	-32.99	-52.41	-53.71	-46.36	-29.01
Financing Cash Flow	422.87	-128.36	-764.63	-317.29	580.64
Exchange Rate Effect	-2.15	-14.43	18.5	10.92	-5.56
Net Cash Flow	-45.82	-21.57	-167.88	316.03	-41.57
Free Cash Flow	573.63	216.31	634.01	706.93	390.34
Free Cash Flow Growth	165.19%	-65.88%	-10.31%	81.10%	-11.78%
Free Cash Flow Margin	13.58%	6.05%	19.83%	23.91%	14.98%
Free Cash Flow Per Share	3.91	1.48	4.36	4.90	2.73

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).